{
  "as_of": "2026-11-14",
  "slug": "oral-psoriasis",
  "title": "乾癬口服藥全景",
  "title_en": "Oral Psoriasis Drug Landscape",
  "scope": "以斑塊型乾癬口服全身性藥物為範圍，涵蓋 TYK2、IL-23R、PDE4 及 A3 受體路徑；不把不同試驗的 PASI 比例排成療效榜。",
  "scope_en": "Oral systemic drugs for plaque psoriasis, covering TYK2, IL-23R, PDE4 and A3 receptor approaches. PASI results from different trials are not an efficacy league table.",
  "short_answers": [
    "截至 2026-11-14，BMS Sotyktu 與 J&J Icotyde 均有美國乾癬核准；武田 zasocitinib 已受理優先審查，屬後續監管競爭者。",
    "Alumis 於 2026-11-12 企業更新重述 envudeucitinib 在 ONWARD3 第 48 週 PASI 100 反應率為 54%；這是延伸試驗資料，不是與其他藥物直接比較。",
    "武田於 2026-09-14 公告 zasocitinib 的 FDA 審查目標落在 2027 年第一季；該決定會改變已核准口服藥的競爭格局。"
  ],
  "short_answers_en": [
    "As of 2026-11-14, BMS’s Sotyktu and J&J’s Icotyde had US psoriasis approvals; Takeda’s zasocitinib was under Priority Review as a regulatory challenger.",
    "Alumis reiterated on 2026-11-12 that 54% achieved PASI 100 at Week 48 in ONWARD3 with envudeucitinib; this extension result is not a head-to-head comparison.",
    "Takeda announced on 2026-09-14 that the FDA target action window for zasocitinib was Q1 2027; that decision could change competition among approved oral drugs."
  ],
  "asia_section": "日本武田是本頁亞洲主軸：zasocitinib 同時有全球三期及與 deucravacitinib 直接比較的資料。本頁將同為口服的 PDE4 與 IL-23 受體路徑一起比較；注射藥物及代理權不列入研發梯隊。",
  "asia_section_en": "Japan’s Takeda anchors the Asian coverage, with global Phase 3 and a direct comparison against deucravacitinib. The landscape also compares oral PDE4 and IL-23 receptor approaches; injectable products and distribution rights are outside this development field.",
  "selection_inputs": [
    "R02"
  ],
  "assets": [
    {
      "section": "approved",
      "trials": [],
      "date": "查閱 2026-11-14",
      "sources": [
        "https://packageinserts.bms.com/pi/pi_sotyktu.pdf"
      ],
      "source_ids": [
        "pso-bms"
      ],
      "asia": false,
      "retrieved_at": "2026-11-14",
      "deal": "查無",
      "deal_en": "Not found",
      "asset": "Sotyktu／deucravacitinib",
      "asset_en": "Sotyktu / deucravacitinib",
      "company": "必治妥施貴寶",
      "company_en": "Bristol Myers Squibb",
      "country": "美國",
      "country_en": "US",
      "mechanism": "變構型 TYK2 抑制劑",
      "mechanism_en": "Allosteric TYK2 inhibitor",
      "route": "口服",
      "route_en": "Oral",
      "stage": "美國已核准",
      "stage_en": "US approved",
      "indication": "成人斑塊型乾癬",
      "indication_en": "Adult plaque psoriasis",
      "latest": "已核准 TYK2 比較基準",
      "latest_en": "Approved TYK2 benchmark"
    },
    {
      "section": "approved",
      "trials": [],
      "date": "2026-03-17",
      "sources": [
        "https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-icotyde"
      ],
      "source_ids": [
        "pso-jnj"
      ],
      "asia": false,
      "retrieved_at": "2026-11-14",
      "deal": "查無",
      "deal_en": "Not found",
      "asset": "Icotyde／icotrokinra",
      "asset_en": "Icotyde / icotrokinra",
      "company": "嬌生",
      "company_en": "Johnson & Johnson",
      "country": "美國",
      "country_en": "US",
      "mechanism": "IL-23 受體拮抗胜肽",
      "mechanism_en": "IL-23 receptor antagonist peptide",
      "route": "口服",
      "route_en": "Oral",
      "stage": "美國已核准",
      "stage_en": "US approved",
      "indication": "12 歲以上、至少 40 kg 的中重度斑塊型乾癬",
      "indication_en": "Moderate-to-severe plaque psoriasis, age 12+, at least 40 kg",
      "latest": "FDA 2026-03-17 核准；四項試驗共 2,500 人；3/18 為公司新聞日",
      "latest_en": "FDA approval 2026-03-17; four trials, 2,500 participants; company release dated March 18"
    },
    {
      "section": "clinical",
      "trials": [
        "NCT06973291"
      ],
      "date": "2026-09-30",
      "sources": [
        "https://www.takeda.com/newsroom/newsreleases/2026/fda-priority-review-zasocitinib-psoriasis/",
        "https://www.takeda.com.cn/newsroom/2026/zasocitinib-superior-efficacy/"
      ],
      "source_ids": [
        "pso-takeda",
        "pso-takeda-data"
      ],
      "asia": true,
      "retrieved_at": "2026-11-14",
      "deal": "查無",
      "deal_en": "Not found",
      "asset": "zasocitinib／TAK-279",
      "asset_en": "zasocitinib / TAK-279",
      "company": "武田",
      "company_en": "Takeda",
      "country": "日本",
      "country_en": "Japan",
      "mechanism": "TYK2 抑制劑",
      "mechanism_en": "TYK2 inhibitor",
      "route": "口服",
      "route_en": "Oral",
      "stage": "FDA 優先審查中",
      "stage_en": "FDA Priority Review",
      "indication": "中重度斑塊型乾癬",
      "indication_en": "Moderate-to-severe plaque psoriasis",
      "latest": "LATITUDE Atlas 與 deucravacitinib 直接比較；審查目標 2027 年第一季",
      "latest_en": "Head-to-head LATITUDE Atlas versus deucravacitinib; FDA target Q1 2027"
    },
    {
      "section": "clinical",
      "trials": [],
      "date": "2026-11-12",
      "sources": [
        "https://investors.alumis.com/news-releases/news-release-details/alumis-reports-third-quarter-2026-financial-results-and",
        "https://www.alumis.com/pipeline/envudeucitinib-for-psoriasis/"
      ],
      "source_ids": [
        "pso-alumis",
        "pso-alumis-pipeline"
      ],
      "asia": false,
      "retrieved_at": "2026-11-14",
      "deal": "查無",
      "deal_en": "Not found",
      "asset": "envudeucitinib",
      "asset_en": "envudeucitinib",
      "company": "Alumis",
      "company_en": "Alumis",
      "country": "美國",
      "country_en": "US",
      "mechanism": "TYK2 抑制劑",
      "mechanism_en": "TYK2 inhibitor",
      "route": "口服",
      "route_en": "Oral",
      "stage": "三期結果；擬送件",
      "stage_en": "Phase 3 results; filing planned",
      "indication": "中重度斑塊型乾癬",
      "indication_en": "Moderate-to-severe plaque psoriasis",
      "latest": "48 週 PASI 100 為 54%；計畫 2026 年第四季送件",
      "latest_en": "Week 48 PASI 100: 54%; NDA planned Q4 2026"
    },
    {
      "section": "approved",
      "trials": [],
      "date": "查閱 2026-11-14",
      "sources": [
        "https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6b1f516-4972-4d82-bced-113e47b41cc5"
      ],
      "source_ids": [
        "pso-amgen"
      ],
      "asia": false,
      "retrieved_at": "2026-11-14",
      "deal": "查無",
      "deal_en": "Not found",
      "asset": "Otezla／apremilast",
      "asset_en": "Otezla / apremilast",
      "company": "安進",
      "company_en": "Amgen",
      "country": "美國",
      "country_en": "US",
      "mechanism": "PDE4 抑制劑",
      "mechanism_en": "PDE4 inhibitor",
      "route": "口服",
      "route_en": "Oral",
      "stage": "美國已核准",
      "stage_en": "US approved",
      "indication": "斑塊型乾癬，年齡及體重依標籤",
      "indication_en": "Plaque psoriasis; label-specific age and weight requirements",
      "latest": "既有口服基準，與 TYK2 路徑分列",
      "latest_en": "Established oral comparator, distinct from TYK2"
    },
    {
      "section": "clinical",
      "trials": [
        "NCT06643260"
      ],
      "date": "查閱 2026-11-14",
      "sources": [
        "https://www.canfite.com/category/PIPELINE-Overview"
      ],
      "source_ids": [
        "pso-canfite"
      ],
      "asia": true,
      "retrieved_at": "2026-11-14",
      "deal": "查無",
      "deal_en": "Not found",
      "asset": "piclidenoson／CF101",
      "asset_en": "piclidenoson / CF101",
      "company": "Can-Fite",
      "company_en": "Can-Fite",
      "country": "以色列",
      "country_en": "Israel",
      "mechanism": "A3 腺苷受體致效劑",
      "mechanism_en": "A3 adenosine receptor agonist",
      "route": "口服",
      "route_en": "Oral",
      "stage": "官網列三期",
      "stage_en": "Phase 3 on company pipeline",
      "indication": "斑塊型乾癬",
      "indication_en": "Plaque psoriasis",
      "latest": "新機制候選；不將未公告結果當成已成功",
      "latest_en": "Investigational mechanism; unreported outcomes are not assumed"
    }
  ],
  "number_checks": [
    [
      "P1",
      "Alumis ONWARD3 第 48 週 PASI 100",
      "54%",
      "pso-alumis",
      "54%"
    ],
    [
      "P2",
      "上述 ONWARD3 時間點",
      "48 週",
      "pso-alumis",
      "48 weeks"
    ],
    [
      "P3",
      "Icotyde 核准年齡下限",
      "12 歲",
      "pso-jnj",
      "12 years"
    ],
    [
      "P4",
      "Icotyde 核准體重下限",
      "40 kg",
      "pso-jnj",
      "40 kg"
    ],
    [
      "P5",
      "Icotyde 四試驗總人數",
      "2,500 人",
      "pso-jnj",
      "2,500"
    ]
  ],
  "not_listed_unconfirmed": [],
  "not_listed_note": "",
  "not_listed_note_en": "",
  "summary_expected": {
    "total": 6,
    "approved": 3,
    "clinical": 3,
    "phase2_3": 0,
    "discontinued": 0,
    "asia": 2,
    "taiwan": 0
  }
}
